An observational study in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University Cancer Hospital & Institute. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Peking University Cancer Hospital & Institute · Observational
Among 400 studies in Esophageal Squamous Cell Carcinoma with a site in China — 174 open to participants now, 212 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.
Among the 400 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 33rd largest by planned enrollment of the 49 observational ones, is one of 47 that started in 2026, is one of 49 observational ones, reaches primary completion later than 109 of the 211 other live ones, and was the 398th registered.
675 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 267 are open to participants now.
This study's planned enrollment of 100 is below the median of 247 across 86 observational studies indexed under Esophageal Squamous Cell Carcinoma.
Browse Esophageal Squamous Cell Carcinoma studies →174 of the 400 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now, in 12 countries. Each count lists the studies.
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →400 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 47 started in 2026.
Median enrollment 70 across the 351 interventional studies, 210 across the 49 observational. Of the 92 that completed or were terminated, 11 (12%) have results posted.
49 of 400 have an industry lead sponsor. The 10 most frequent:
Peking University Cancer Hospital & Institute is the lead sponsor of 268 studies on the registry; 128 are open to participants now.
Peking University Cancer Hospital & Institute has 8 studies filed under Esophageal Squamous Cell Carcinoma — fewer than ten, so there is no comparison to draw.
47 of the studies in Esophageal Squamous Cell Carcinoma with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06194734Phase 3Beijing Konruns Pharmaceutical Co., Ltd.A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | 2026-12-30 |
| NCT06907602Phase 3Peking Union Medical College HospitalOptimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma | 2026-12-31 |
| NCT04848753Phase 3Shanghai Junshi Bioscience Co., Ltd.Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 2027-05-12 |
| NCT04550260Phase 3AstraZenecaStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | 2027-06-30 |
| NCT07016737Phase 3Ye jinjunImmunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy | 2027-09-01 |
Among the 400 studies in Esophageal Squamous Cell Carcinoma with a site in China, from their registry updates:
This observational study aims to understand the risk of cancer returning after surgery in people with esophageal squamous cell carcinoma, a type of cancer of the food pipe. It focuses on people who received immunotherapy and chemotherapy before surgery.
Researchers will review existing medical records, scans, reports on tissue removed during surgery, and follow-up information. They will examine when and where cancer returns and which patient characteristics, treatment details, scan findings, and tissue findings are associated with its return.
All treatment and tests were part of routine care. The study does not assign treatment or require additional scans, tissue collection, or follow-up visits.
The source population comprises adults who underwent esophagectomy for esophageal squamous cell carcinoma at the study institution between August 1, 2020, and October 31, 2025. Patients will be identified through institutional medical records, imaging archives, surgical and pathology registries, and existing follow-up records. All patients within this surgical window who received neoadjuvant immunochemotherapy and meet the eligibility criteria will be included. No random sampling will be performed. Documented postoperative outcomes will be reviewed through December 1, 2025.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed esophageal squamous cell carcinoma.
Receipt of immunochemotherapy, defined as an combined with chemotherapy, followed by curative esophagectomy between August 1, 2020, and October 31, 2025.
Microscopically negative surgical margins (R0 resection), postoperative M0 status confirmed on review using the American Joint Committee on Cancer eighth edition staging system, and verifiable postoperative ypT and ypN categories.
Availability of FDG PET/CT performed after completion of neoadjuvant treatment and before surgery, together with a verifiable surgery date, recurrence status, and valid follow-up dates. Availability of pretreatment PET/CT is not required.
Exclusion Criteria:
Death within 30 days after surgery or absence of any verifiable postoperative outcome follow-up.
Missing essential pathological staging information, or survival data that prevent confirmation of eligibility or determination of the primary outcome despite review of source records. Missing nonessential variables alone will not result in exclusion.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with histologically confirmed esophageal squamous cell carcinoma who underwent curative esophagectomy between August 1, 2020, and October 31, 2025, after neoadjuvant immunochemotherapy. Existing clinical records, FDG PET/CT findings, surgical pathology reports, and postoperative follow-up records will be reviewed to assess recurrence risk and associated factors. All treatments and examinations were provided as part of routine clinical care and were not assigned by this study.
Recurrence-Free Survival
Time, in months, from surgery to the first documented local, regional, or distant recurrence, determined using imaging, pathology, or documented clinical assessment. Participants without recurrence will be censored at their last disease assessment. Death without documented recurrence is not an RFS event; these participants will be censored at their last disease assessment before death. RFS probabilities at 12 and 24 months after surgery will be estimated using the Kaplan-Meier method.
Time frame: From surgery through December 1, 2025, up to 64 months.
Plan to share: Undecided — Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esophageal Squamous Cell Carcinoma →
Peking University Cancer Hospital & Institute →